This study evaluates a new aqueous nasal formulation of ipratropium bromide (Atrovent Nasal Spray 0.03%) in subjects with perennial non-allergic rhinitis in a double-blind, placebo-controlled trial.

The APN possesses the advanced clinical knowledge and skills to be able to synthesize the assessment information and create a comprehensive plan -- including pharmacologic and nonpharmacologic ...